Keyword: Sanofi

Sanofi is trumpeting new data for a hemophilia A drug developed by Bioverativ that it says could transform treatment of the bleeding disorder.

The drug shrunk the tumors of most patients in the trial, raising hopes it can become a new treatment option for patients with RET-altered cancers.

HiFiBiO Therapeutics has completed a $37.5 million series B funding round after expanding its leadership team last summer.

A pilot showed X4’s anti-PD-1 combination spurred activity in patients that didn’t respond to Opdivo treatment alone, with a drug bought from Sanofi.

Gene analysis on 800 milkshake drinkers could guide new research in cardiovascular disease.

Sanofi says its GLP-1 drug SAR425899 is undertaking new tests to try to get around dosing issues that is causing GI problems.

Sanofi hires ex-Roche executive as R&D chief, Advaxis names former Rosetta Genomics chief as CEO, and Urovant steals Allergan’s key urology VP.

The deal sparked a 30% jump in Adocia’s stock price as investors cheered evidence the biotech is gaining momentum after being dumped by Eli Lilly.

Zerhouni is to retire from the position at the end of June, leaving former Roche research leader John Reed to take charge of Sanofi’s pipeline.

GSK steals Roche exec to lead R&D deal-making, Sanofi CFO Contamine will retire, Novartis poaches Amgen's CMO, FDA CDER director jumps to AZ.